DOCSLIB.ORG

572 Antihistamines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
572 Antihistamines 572 Antihistamines Dexchlorpheniramine Maleate (BANM, rINNM) rphenamine is widely distributed in the body, and en- polistirex (a sulfonated diethenylbenzene-ethenylben- Dekschlorfeniramino maleatas; Dekskloorifeniramiinimaleaatti; ters the CNS. zene copolymer complex), chlorphenamine tannate, Dexchlorfeniramin-maleinát; Dexchlorphenamine Maleate; Dex- Chlorphenamine maleate is extensively metabolised. and dexchlorpheniramine tannate are given orally and chlorphéniramine, Maléate de; Dexchlorpheniramini maleas; Metabolites include desmethyl- and didesmethylchlo- are used similarly to the maleate. Dexklorfeniraminmaleat; Dexklórfeniramin-maleát; Maleato de rphenamine. Unchanged drug and metabolites are ex- Malaria. Chlorphenamine may be tried in patients with malaria dexclorfeniramina. creted primarily in the urine; excretion is dependent on who have chloroquine-induced pruritus (see Effects on the Skin, Дексхлорфенирамина Малеат urinary pH and flow rate. Only trace amounts have p.600), but additionally it has been shown to have some promise CAS — 25523-97-1 (dexchlorpheniramine); 2438-32-6 as an adjunct in the treatment of chloroquine-resistant malaria (dexchlorpheniramine maleate). been found in the faeces. itself. Early studies indicated that chlorphenamine was only one ATC — R06AB02. A duration of action of 4 to 6 hours has been reported; of a number of drugs that reversed chloroquine resistance in vitro ATC Vet — QR06AB02. this is shorter than may be predicted from pharmacok- in isolates of Plasmodium falciparum. Later clinical studies in inetic parameters. children in Nigeria showed enhanced efficacy when chlorphen- amine was given with chloroquine.1-5 The overall management Cl More rapid and extensive absorption, faster clearance, of malaria is discussed on p.594. CH3 and a shorter half-life have been reported in children. 1. Sowunmi A, et al. Enhanced efficacy of chloroquine-chlorphe- niramine combination in acute uncomplicated falciparum malar- N ◊ References. ia in children. Trans R Soc Trop Med Hyg 1997; 91: 63–7. H3C 1. Rumore MM. Clinical pharmacokinetics of chlorpheniramine. 2. Sowunmi A, Oduola AMJ. Comparative efficacy of chloro- Drug Intell Clin Pharm 1984; 18: 701–7. quine/chlorpheniramine combination and mefloquine for the 2. Paton DM, Webster DR. Clinical pharmacokinetics of H -recep- treatment of chloroquine-resistant Plasmodium falciparum ma- N tor antagonists (the antihistamines). Clin Pharmacokinet 1985; laria in Nigerian children. Trans R Soc Trop Med Hyg 1997; 91: 10: 477–97. 689–93. 3. Yasuda SU, et al. The roles of CYP2D6 and stereoselectivity in 3. Sowunmi A, et al. Comparative efficacy of chloroquine plus the clinical pharmacokinetics of chlorpheniramine. Br J Clin chlorpheniramine and pyrimethamine/sulfadoxine in acute un- Pharmacol 2002; 53: 519–25. complicated falciparum malaria in Nigerian children. Trans R (dexchlorpheniramine) Soc Trop Med Hyg 1998; 92: 77–81. 4. Sowunmi A, et al. Comparative efficacy of chloroquine plus Pharmacopoeias. In Eur. (see p.vii), Jpn, and US. Uses and Administration chlorpheniramine and halofantrine in acute uncomplicated falci- Ph. Eur. 6.2 (Dexchlorpheniramine Maleate). A white or almost Chlorphenamine maleate, an alkylamine derivative, is parum malaria in Nigerian children. Trans R Soc Trop Med Hyg 1998; 92: 441–5. white, crystalline powder. Very soluble in water; freely soluble in a sedating antihistamine that causes a moderate degree 5. Okonkwo CA, et al. Effect of chlorpheniramine on the pharma- alcohol, in dichloromethane, and in methyl alcohol. A 1% solu- of sedation; it also has antimuscarinic activity. cokinetics of and response to chloroquine of Nigerian children tion in water has a pH of 4.5 to 5.5. Protect from light. with falciparum malaria. Trans R Soc Trop Med Hyg 1999; 93: USP 31 (Dexchlorpheniramine Maleate). A white, odourless, Chlorphenamine is a racemic mixture; the dextrorota- 306–11. crystalline powder. Soluble 1 in 1.1 of water, 1 in 2 of alcohol, 1 tory isomer, dexchlorpheniramine, has about twice the Preparations in 1.7 of chloroform, and 1 in 2500 of ether; slightly soluble in activity of chlorphenamine by weight. BP 2008: Chlorphenamine Injection; Chlorphenamine Oral Solution; Chlo- benzene. pH of a 1% solution in water is between 4.0 and 5.0. rphenamine Tablets; Store in airtight containers. Protect from light. Chlorphenamine maleate and dexchlorpheniramine USP 31: Acetaminophen, Chlorpheniramine Maleate, and Dextromethor- maleate are used for the symptomatic relief of allergic phan Hydrobromide Tablets; Chlorpheniramine Maleate and Phenylpropa- nolamine Hydrochloride Extended-release Capsules; Chlorpheniramine Adverse Effects and Precautions conditions including urticaria and angioedema (p.565), Maleate and Phenylpropanolamine Hydrochloride Extended-release Tab- rhinitis (p.565), and conjunctivitis (p.564), and in pru- lets; Chlorpheniramine Maleate and Pseudoephedrine Hydrochloride Ex- As for the sedating antihistamines in general, p.561. tended-release Capsules; Chlorpheniramine Maleate and Pseudoephedrine Exfoliative dermatitis may develop. Injections may be ritic skin disorders (p.565). They are common ingredi- Hydrochloride Oral Solution; Chlorpheniramine Maleate Extended-release ents of compound preparations for symptomatic treat- Capsules; Chlorpheniramine Maleate Injection; Chlorpheniramine Maleate irritant and cause transient hypotension or stimulation Syrup; Chlorpheniramine Maleate Tablets; Dexchlorpheniramine Maleate of the CNS. ment of coughs and the common cold (p.564). Syrup; Dexchlorpheniramine Maleate Tablets. However, such preparations should be used with cau- Effects on the blood. There are several old and isolated re- Proprietary Preparations (details are given in Part 3) tion in children, and generally avoided in those under 2 Arg.: Afeme; Alergidryl†; Alergitrat; Isomerine†; Qura Plus; Austral.: Polar- ports of blood dyscrasias after use of chlorphenamine maleate; amine; Austria: Polaramin; Belg.: Polaramine†; Braz.: Alergonil; Alergov- these include agranulocytosis,1,2 thrombocytopenia,3 pancytope- years of age (see p.562). Chlorphenamine may be giv- alle†; Alergyo; Alermine†; Deflux†; Dexclor†; Dexlerg; Dexmin†; Ex- nia,4 and aplastic anaemia.5 Haemolytic anaemia has occurred en intravenously as an adjunct in the emergency treat- pectamin F; Histamin; Hystin; Polamin†; Polaramine; Polaren; Polaryn; after use of dexchlorpheniramine maleate.6 The association with ment of anaphylactic shock (p.563). Canad.: Chlor-Tripolon; Novo-Pheniram; Chile: Asafen Nueva Formula†; antihistamine use has been questioned in some of these cases.7 Clorprimeton; Nipolen; Prodel; Scadan; Denm.: Polaramin; Fr.: Polaramine; Chlorphenamine maleate is given in oral doses of 4 mg Ger.: Polaronil; Gr.: Istamex; Polaramine†; Hong Kong: Allermin; Apomin; 1. Shenfield G, Spry CJF. Unusual cause of agranulocytosis. BMJ Chlorpyrimine; Dapriton; Kenyamine; Medifen†; Pirimat; Piriton†; Polara- 1968; ii: 52–3. every 4 to 6 hours up to a maximum of 24 mg daily. mine; Rhiniramine; Sprinsol†; Synchloramin; Uni-Ramine; India: Cofton; In- 2. Hardin AS. Chlorpheniramine and agranulocytosis. Ann Intern Doses for children, according to age, are: 1 to 2 years, don.: Chlorphenon; Cohistan; CTM; Orphen; Pehachlor; Polamec; Polara- Med 1988; 108: 770. mine; Polarist; Polofar; Irl.: Piriton; Israel: Ahiston; Anaphyl†; Ital.: 3. Eisner EV, et al. Chlorpheniramine-dependent thrombocytope- 1 mg twice daily; 2 to 5 years, 1 mg every 4 to 6 hours Polaramin; Trimeton; Malaysia: Chloramine†; Chlormine; Chlorpyrimine; nia. JAMA 1975; 231: 735–6. (maximum 6 mg daily); 6 to 12 years, 2 mg every 4 to D-Antihist†; Dex-Antihist†; Dexchloramine; Polamine†; Polaramine; Somin; Mex.: Alerdil; Antadex-H; Blendox; Cloro-Trimeton; Cronal; Docsi; Hi- 4. Deringer PM, Maniatis A. Chlorpheniramine-induced bone-mar- 6 hours (maximum 12 mg daily). Although not li- erbal; Histadryl; Polaramine†; Neth.: Polaramine; Norw.: Phenamin; Polar- row suppression. Lancet 1976; i: 432. censed in the UK, the BNFC suggests that children amin; NZ: Histafen; Polaramine; Philipp.: Antamin; Barominic; Chlor-Tri- 5. Kanoh T, et al. Aplastic anaemia after prolonged treatment with meton; Valemine; Virgomine; Port.: Trenelone; S.Afr.: Allergex; Chlor- chlorpheniramine. Lancet 1977; i: 546–7. aged 1 month and over may be given 1 mg twice daily. Trimeton†; Chlorhist†; Polaramine†; Rhineton; Singapore: Allerphen†; 6. Duran-Suarez JR, et al. The I antigen as an immune complex Chloramine; Chlorpyrimine; Dexchloramine; Dextramine; Piriton; Polara- receptor in a case of haemolytic anaemia induced by an antihis- Chlorphenamine maleate may be given by intramuscu- mine; Rhiniramine; Somin; Spain: Antihistaminico; Polaramine; Swed.: Po- taminic agent. Br J Haematol 1981; 49: 153–4. lar, by subcutaneous, or by slow intravenous injection laramin; Switz.: Polaramine; Thai.: Allergin†; Chlorleate; Chlorpheno; 7. Spry CJF. Chlorpheniramine-induced bone-marrow suppression. Chlorpyrimine; Cohistan; Histatab; Histatapp; Icolid Plus; Kloramin; Na- Lancet 1976; i: 545. over a period of 1 minute. The usual dose is 10 to samine†; Piriton†; UAE: Chlorohistol; UK: Allercalm; Allergy Relief; Allerief; 20 mg and the total dose given by these routes in 24 Calimal; Hayleve; Piriton; Pollenase Antihistamine; USA: Aller-Chlor; Aller- Effects on the senses. Chlorphenamine has been reported to gy; Allergy Relief; Chlo-Amine; Chlor-Pro; Chlor-Trimeton; ChlorTan; Ed- affect the senses of smell and taste.1 hours should not normally exceed
Load more

Recommended publications
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Biperiden and Chlorphenoxamine) in Various Dosage Forms by Spectrophotometry
    International Journal of Chemical and Analytical Science ISSN: 0976-1206 Research Article www.ijcas.info Simultaneous Determination of some anticholinergic drugs (Biperiden and Chlorphenoxamine) in Various Dosage forms by Spectrophotometry Issa FAA1, EL-Helbawy SM2 and Abed EL- Magied AM2* 1Chemistry Department, faculty of science, Menoufia University 2Medico-Legal organization, Ministry of Justice, Cairo, Egypt Simple and rapid spectrophotometric procedures were established for quantization of biperiden hydrochloride (BPN) and chlorphenoxamine hydrochloride (CPA). The procedures are based on the reaction between the examined drugs BPN and CPA and picric acid (I), alizarin (II), bromothymol blue (III) and chlorophenol red (IV) producing ion-associates which can be measured at the optimum wavelength. The optimization of the reaction conditions was investigated. Beer’s law is obeyed in the concentration ranges 58.8 –166.4 µgml−1. The molar absorptivity, Sandell sensitivity are also calculated. The correlation coefficient was ≥0.9996 (n = 6) with a relative standard deviation (R.S.D.) ≤1.35 for four determinations. The methods are successfully applied to determine of BPN and CPA in pharmaceutical formulations. Keywords: Spectrophotometry, Ion-Associates, Drugs, Biperiden, Chlorphenoxamine INTRODUCTION MATERIALS AND METHODS Biperiden hydrochloride (BPN) is α-Bicyclo [2.2.1] hept–5–en– Apparatus: The spectral measurements were carried out by 2–yl-α-phenyl–1–piperidinepropanol. Chlorphenoxamine using U.V-visible spectrophotometer (Helios Alpha) with a hydrochloride (CPA) is 2-[1-(4-Chlorophenyl)-1–phenyl- 10mm quartz cell, optical path length was used. phenylethoxy]-N, N-dimethylethanamine. They are a weak peripheral anticholinergic[1,2] Agent. It has, therefore, some Reagents: Picric acid 2,4,6 tri nitro phenol (I), Alizarin 1,2 di antisecretory, antispasmodic, mydriatic and antihistaminic hydroxy anthraquinone (II), bromothymol blue 3,3 effects.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP001021204B1* (19) European Patent Office Office européen des brevets (11) EP 1 021 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 47/32, A61L 25/00 of the grant of the patent: 28.12.2005 Bulletin 2005/52 (86) International application number: PCT/US1998/020091 (21) Application number: 98949505.6 (87) International publication number: (22) Date of filing: 25.09.1998 WO 1999/015210 (01.04.1999 Gazette 1999/13) (54) BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS BIOLOGISCHE KLEBER UND VERFAHREN ZUR TOPISCHEN VERABREICHUNG VON WIRKSTOFFEN COMPOSITIONS BIOADHESIVES ET METHODES D’ADMINISTRATION LOCALE D’AGENTS ACTIFS (84) Designated Contracting States: • HOUZE, David AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Miami, FL 33186 (US) MC NL PT SE • KANIOS, David Miami, FL 33196 (US) (30) Priority: 26.09.1997 US 61155 P (74) Representative: Isenbruck, Günter (43) Date of publication of application: Isenbruck, Bösl, Hörschler, Wichmann, Huhn 26.07.2000 Bulletin 2000/30 Patentanwälte Theodor-Heuss-Anlage 12 (73) Proprietor: NOVEN PHARMACEUTICALS, INC. 68165 Mannheim (DE) Miami, FL 33186 (US) (56) References cited: (72) Inventors: FR-A- 2 532 546 GB-A- 1 050 070 • MANTELLE, Juan GB-A- 2 046 773 US-A- 4 593 053 Miami, FL 33176 (US) US-A- 5 656 286 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Final1-Aritmo-Final-Report-V2-0Final.Pdf
    ARITMO Final Report PROJECT FINAL REPORT Grant Agreement number: 241679 Project acronym: ARITMO Project title: Arrhythmogenic potential of drugs Funding Scheme: Small or Medium-Scale Focused Research Project Period covered: from 1st January 2010 to 30th June 2013 Name of the scientific representative of the project's co-ordinator, Title and Organisation: Prof. Miriam CJM Sturkenboom, Erasmus Universitair Medisch Centrum Rotterdam Tel: +31 10 704 4126 Fax: +31 10 704 4722 E-mail: [email protected] Project website1 address: www.aritmo-project.org 1 The home page of the website should contain the generic European flag and the FP7 logo which are available in electronic format at the Europa website (logo of the European flag: http://europa.eu/abc/symbols/emblem/index_en.htm ; logo of the 7th FP: http://ec.europa.eu/research/fp7/index_en.cfm?pg=logos). The area of activity of the project should also be mentioned. © Copyright 2013 ARITMO Consortium 1 ARITMO Final Report Table of contents Table of contents ................................................................................................................................................................. 2 1. Final publishable summary report ................................................................................................................................ 3 1.1 Executive summary ................................................................................................................................................. 3 1.2 Description of project context and
    [Show full text]
  • 5- Normal Phase High Performance Liquid Chromatographic Determination of Chlorphenoxamine Hydrochloride, Caffeine and 8-Chlorotheophylline
    5- NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF CHLORPHENOXAMINE HYDROCHLORIDE, CAFFEINE AND 8-CHLOROTHEOPHYLLINE Y. M. Dessouky, H. H. Hassanein, M. Abdul-Azim Mohammad* and R. S. Hanafy** Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasrel-Aiani, 11562, Cairo, Egypt. Received:14-3-2004 Accepted:16-5-2004 Abstract: INTRODUCTION An isocratic, rapid and reproducible high performance liquid chromatographic (HPLC) Chlorphenoxamine hydrochloride (CPHX), [I] method for quantitative determination of chlor- is a histamine H1- receptor antagonist with anti- phenoxamine hydrochloride (CPHX), caffeine muscarinic properties 1. Caffeine (CAFF), [2] is a (CAFF) and 8-chlorotheophylline (CTHE) has been xanthine derivative with CNS stimulant activity 1-3. adopted. The optimal conditions for separation and 8-Chlorotheophylline (CTHE) [3] is also a xanthine quantitative determination of these compounds derivative that forms with dipenhydramine a were a normal phase mode chromatography and compound named dimenhydrinate that is widely isocratic elution at ambient temperature. A silica used for alleviation of motion sickness 1-3. column and a mobile phase consisted of ethyl Combination of the three drugs is known 1,4. acetate - methanol (50:50 v/v) / triethylamine pH 9, CPHX was determined by titrimetric 2, have been used at a flow rate of 1 ml min-1. The electrochemical 5, spectrophotometric 6-8, derivative components of column effluent were monitored by spectrophotometric 9,10, derivative ratio spectro- 11 11 UV detector at 254 nm. The retention times (tR) for photometric , chemometric and spectro- CPHX, CAFF and CTHE were 6.15, 4.23 and 2.97 fluorimetric 12 methods. Chromatographic methods min, respectively.
    [Show full text]